Our findings suggest that the protective effect of CTS against NAFLD in mice may be achieved by inhibiting NPC1L1-mediated intestinal cholesterol absorption. The gene discussed is NPC1L1; the disease is metabolic dysfunction-associated steatotic liver disease.